Abstract Search

ea0081p439 | Reproductive and Developmental Endocrinology | ECE2022

Coexistence of 46, XX testicular disorder of sex development and 11β-hydroxylase deficiency: In Vivo and In Vitro Studies

Sun Bang , Wang Xi , Mao Jiangfeng , Wu Xueyan , Nie Min

Background: 46, XX testicular disorder of sex development (DSD) and 11β-hydroxylase deficiency (11β-OHD) are two extremely rare types of disorder of sex development. No coexistence has been reported yet.Case Description: Here we reported the first patient diagnosed as the coexistence of 11β-OHD and 46, XX testicular DSD basing on clinical, biochemical, molecular, cytogenetic, and functional experiment findings. A 22-year-old male showed sm...

0 shares

ea0099p352 | Reproductive and Developmental Endocrinology | ECE2024

Early response with fezolinetant treatment of moderate-to-severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy: phase 3b daylight study

Linden Hirschberg Angelica , Bouchard Celine , Cano Antonio , Schaudig Katrin , Martins Karla , Miyazaki Kentaro , Wu Xi , Wang Xuegong

Introduction: There is a need for well tolerated and effective nonhormonal therapies for vasomotor symptoms (VMS) associated with menopause. Fezolinetant is a nonhormonal, selective neurokinin 3 receptor antagonist that is approved for the treatment of moderate-to-severe VMS associated with menopause.Objective: To assess how early a response to fezolinetant in frequency and severity of moderate-to-severe VMS was observed in the 24-week placebo-controlled...

0 shares

Endocrine Abstracts

Coexistence of 46, XX testicular disorder of sex development and 11β-hydroxylase deficiency: In Vivo and In Vitro Studies

Early response with fezolinetant treatment of moderate-to-severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy: phase 3b daylight study

BiosciAbstracts